SMMT:NSD-Summit Therapeutics PLC (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 20.885

Change

0.00 (0.00)%

Market Cap

USD 15.35B

Volume

5.65M

Analyst Target

USD 4.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 35.29B
ARGX argenx NV ADR

N/A

USD 32.06B
MRNA Moderna Inc

N/A

USD 25.25B
BGNE BeiGene Ltd

N/A

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

N/A

USD 15.71B
PCVX Vaxcyte Inc

N/A

USD 14.00B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 13.46B

ETFs Containing SMMT

CNCR Loncar Cancer Immunothera.. 6.78 % 0.79 %

N/A

USD 0.01B
BBC Virtus LifeSci Biotech Cl.. 2.33 % 0.79 %

N/A

USD 0.01B
FYC First Trust Small Cap Gro.. 1.33 % 0.70 %

N/A

USD 0.33B
FYX First Trust Small Cap Cor.. 0.51 % 0.63 %

N/A

USD 0.91B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 700.19% 77% C+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 700.19% 77% C+ 90% A-
Trailing 12 Months  
Capital Gain 1,016.84% 81% B- 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,016.84% 81% B- 92% A
Trailing 5 Years  
Capital Gain 1,066.76% 82% B 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,066.76% 82% B 93% A
Average Annual (5 Year Horizon)  
Capital Gain 91.55% N/A N/A 94% A
Dividend Return 91.55% N/A N/A 94% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 197.27% N/A N/A 9% A-
Risk Adjusted Return 46.41% N/A N/A 76% C+
Market Capitalization 15.35B 99% N/A 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector